MARC details
| 000 -LEADER |
|---|
| fixed length control field |
02288nam a2200301Ia 4500 |
| 003 - CONTROL NUMBER IDENTIFIER |
|---|
| control field |
MX-MdCICY |
| 005 - DATE AND TIME OF LATEST TRANSACTION |
|---|
| control field |
20250625162429.0 |
| 040 ## - CATALOGING SOURCE |
|---|
| Transcribing agency |
CICY |
| 090 ## - LOCALLY ASSIGNED LC-TYPE CALL NUMBER (OCLC); LOCAL CALL NUMBER (RLIN) |
|---|
| Classification number (OCLC) (R) ; Classification number, CALL (RLIN) (NR) |
B-19332 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
|---|
| fixed length control field |
250602s9999 xx |||||s2 |||| ||und|d |
| 245 10 - TITLE STATEMENT |
|---|
| Title |
Nanobodies: New ammunition to battle viruses |
| 490 0# - SERIES STATEMENT |
|---|
| Volume/sequential designation |
Antiviral Research, 92(3), p.389-407, 2011 |
| 520 3# - SUMMARY, ETC. |
|---|
| Summary, etc. |
In 1989, a new type of antibody was identified, first in the sera of dromedaries and later also in all other species of the Camelidae family. These antibodies do not contain a light chain and also lack the first constant heavy domain. Today it is still unclear what the evolutionary advantage of such heavy chain-only antibodies could be. In sharp contrast, the broad applicability of the isolated variable antigen-binding domains (VHH)was rapidly recognized, especially for the development of therapeutic proteins, called Nanobodies_. Here we summarize first some of the unique characteristics and features of VHHs. These will next be described in the context of different experimental therapeutic applications of Nanobodies against different viruses: HIV, Hepatitis B virus, influenza virus, Respiratory Syncytial virus, Rabies virus, FMDV, Poliovirus, Rotavirus, and PERVs. Next, the diagnostic application of VHHs (Vaccinia virus, Marburg virus and plant Tulip virus X), as well as an industrial application (lytic lactococcal 936 phage)will be described. In addition, the described data show that monovalent Nanobodies can possess unique characteristics not observed with conventional antibodies. The straightforward formatting into bivalent, multivalent, and/or multispecific Nanobodies allowed tailoring molecules for potency and cross-reactivity against viral targets with high sequence diversity. |
| 650 14 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
NANOBODY |
| 650 14 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
CAMELIDAE |
| 650 14 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
HEAVY CHAIN-ONLY ANTIBODY |
| 650 14 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
VHH |
| 650 14 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
ANTIVIRAL |
| 700 12 - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Vanlandschoot, P. |
| 700 12 - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Stortelers, C. |
| 700 12 - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Beirnaert, E. |
| 700 12 - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Ibañez, L. I. |
| 700 12 - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Schepens, B. |
| 700 12 - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Depla, E. |
| 700 12 - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Saelens, X. |
| 856 40 - ELECTRONIC LOCATION AND ACCESS |
|---|
| Uniform Resource Identifier |
<a href="https://drive.google.com/file/d/1_0J9YNFwKXQeF8u2aT6jL7hVe5nPo6Ou/view?usp=drivesdk">https://drive.google.com/file/d/1_0J9YNFwKXQeF8u2aT6jL7hVe5nPo6Ou/view?usp=drivesdk</a> |
| Public note |
Para ver el documento ingresa a Google con tu cuenta: @cicy.edu.mx |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) |
|---|
| Source of classification or shelving scheme |
Clasificación local |
| Koha item type |
Documentos solicitados |
